-
公开(公告)号：US20150232460A1
公开(公告)日：2015-08-20
申请号：US14625812
申请日：2015-02-19
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , Stephanie Maine , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: C07D413/12 , A61K31/44 , C07D239/42 , A61K31/505 , C07D403/12 , A61K45/06 , C07D401/12 , A61K31/4439 , A61K31/497 , C07D241/20 , A61K31/4965 , C07D213/74 , A61K31/506
CPC classification number: C07D403/12 , A61K31/44 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/74 , C07D239/42 , C07D241/20 , C07D401/12 , C07D401/14 , C07D413/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中L，X，Ra，Rb，R 1，R 2和R 3如本说明书中所定义，其制备方法，含有它们的药物组合物及其在 治疗。
-
公开(公告)号：US10689373B2
公开(公告)日：2020-06-23
申请号：US15995586
申请日：2018-06-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , Stephanie Maine , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: A61K31/44 , C07D413/12 , C07D213/74 , C07D239/42 , C07D401/14 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/506 , A61K45/06 , C07D241/20 , C07D401/12 , C07D403/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
-
3.发明授权Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders 有权环戊基苯甲酰胺衍生物及其用于治疗精神病和认知障碍的用途公开(公告)号：US09493432B2
公开(公告)日：2016-11-15
申请号：US15029356
申请日：2014-10-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , John Stephen Robinson , Tatsuhiko Fujimoto
IPC: C07D277/82 , C07D241/44 , C07D401/12 , C07D263/58 , C07D413/12 , C07D417/14 , C07D417/12 , C07D277/64 , C07D403/12 , C07D215/12 , C07D513/04
CPC classification number: C07D277/82 , A61K31/423 , A61K31/428 , A61K31/47 , A61K31/498 , C07D215/12 , C07D241/44 , C07D263/58 , C07D277/64 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/12 , C07D513/04 , A61K2300/00
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
-
4.发明授权公开(公告)号：US09156829B2
公开(公告)日：2015-10-13
申请号：US14625812
申请日：2015-02-19
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , Stephanie Maine , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: A61K31/4965 , C07D401/00 , C07D405/00 , C07D213/46 , C07D413/12 , C07D213/74 , A61K31/44 , C07D239/42 , A61K31/505 , C07D403/12 , A61K31/506 , C07D401/12 , A61K31/4439 , A61K31/497 , C07D241/20 , A61K45/06
CPC classification number: C07D403/12 , A61K31/44 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/74 , C07D239/42 , C07D241/20 , C07D401/12 , C07D401/14 , C07D413/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中L，X，Ra，Rb，R 1，R 2和R 3如本说明书中所定义，其制备方法，含有它们的药物组合物及其在 治疗。
-
公开(公告)号：US20180282309A1
公开(公告)日：2018-10-04
申请号：US15995586
申请日：2018-06-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , Stephanie Maine , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: C07D403/12 , C07D401/14 , C07D413/12 , A61K45/06 , C07D241/20 , C07D401/12 , A61K31/44 , C07D213/74 , A61K31/506 , A61K31/505 , A61K31/497 , A61K31/4965 , A61K31/4439 , C07D239/42
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
-
Patent Agency Ranking
公开(公告)号：US10011588B2
公开(公告)日：2018-07-03
申请号：US15120048
申请日：2015-02-19
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , Stephanie Maine , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: C07D403/12 , C07D213/74 , C07D239/42 , A61K31/44 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/506 , A61K45/06 , C07D241/20 , C07D401/12 , C07D413/12 , C07D401/14
CPC classification number: C07D413/12 , A61K31/44 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/74 , C07D239/42 , C07D241/20 , C07D401/12 , C07D401/14 , C07D403/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
-
公开(公告)号：US09750748B2
公开(公告)日：2017-09-05
申请号：US14652484
申请日：2013-12-17
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： William Farnaby , Charlotte Fieldhouse , Katherine Hazel , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller
IPC: A61K31/55 , C07D405/04 , A61K31/501 , C07D403/04 , C07D237/20 , C07D401/04 , A61K45/06 , A61K31/50 , C07D237/16 , C07D237/22 , A61K31/277 , A61K31/496 , A61K31/519 , A61K31/53 , A61K31/551 , A61K31/554 , A61K33/00
CPC classification number: A61K31/55 , A61K31/277 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/519 , A61K31/53 , A61K31/551 , A61K31/554 , A61K33/00 , A61K45/06 , C07D237/16 , C07D237/20 , C07D237/22 , C07D401/04 , C07D403/04 , C07D405/04 , A61K2300/00
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
-
8.发明申请Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders 有权环戊基苯甲酰胺衍生物及其用于治疗精神病和认知障碍的用途公开(公告)号：US20160222030A1
公开(公告)日：2016-08-04
申请号：US15029356
申请日：2014-10-14
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Charlotte Fieldhouse , Angela Glen , John Stephen Robinson , Tatsuhiko Fujimoto
IPC: C07D513/04 , A61K31/498 , C07D277/82 , A61K31/428 , C07D263/58 , A61K31/4184 , C07D417/12 , C07D401/12 , A61K31/4709 , C07D403/12 , C07D215/12 , C07D277/64 , A61K31/506 , A61K31/517 , A61K31/437 , C07D413/12 , A61K31/4245 , C07D417/14 , A61K45/06 , C07D241/54
CPC classification number: C07D277/82 , A61K31/423 , A61K31/428 , A61K31/47 , A61K31/498 , C07D215/12 , C07D241/44 , C07D263/58 , C07D277/64 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/12 , C07D513/04 , A61K2300/00
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中n，L，X，Ra，Rb，R 1，R 2和R 3的制备，含有它们的药物组合物及其在治疗中的用途。
-
9.发明授权公开(公告)号：US09790220B2
公开(公告)日：2017-10-17
申请号：US15120002
申请日：2015-02-19
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Charlotte Fieldhouse , Angela Glen , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: A61K31/015 , A61K31/16 , C07D417/14 , C07D401/12 , C07D413/12 , C07D417/12 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/498
CPC classification number: C07D417/14 , A61K31/015 , A61K31/16 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/498 , C07D401/12 , C07D413/12 , C07D417/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
-
10.发明申请SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS 有权取代环孢菌素，四氢呋喃和吡咯烷作为OREXIN受体拮抗剂公开(公告)号：US20170073340A1
公开(公告)日：2017-03-16
申请号：US15120002
申请日：2015-02-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Charlotte Fieldhouse , Angela Glen , Tatsuhiko Fujimoto , John Stephen Robinson
IPC: C07D417/14 , A61K31/4439 , A61K31/4709 , A61K31/4545 , C07D401/12 , A61K31/498 , C07D417/12 , C07D413/12
CPC classification number: C07D417/14 , A61K31/015 , A61K31/16 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/498 , C07D401/12 , C07D413/12 , C07D417/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，式（I）其中L，X，Ra，Rb，R 1，R 2和R 3如本说明书中所定义，其制备方法，含有 他们和他们在治疗中的用途。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
